Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 434 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Vascular Disorders Clear all

Conditions: Diabetic Retinopathy
Interventions: PAN-90806 Ophthalmic Solution; Drug
Lead sponsor: PanOptica, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Harlingen, Texas • McAllen, Texas

Conditions: Diabetic Retinopathy
Interventions: Retinal imaging, Mydriatic Agent; Procedure · Drug
Lead sponsor: Eyenuk, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Idaho Falls, Idaho

Conditions: Diabetic Retinopathy
Interventions: AKST4290, Placebo; Drug
Lead sponsor: Alkahest, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 17
States / cities: Phoenix, Arizona • Glendale, California • Huntington Beach, California + 13 more

Conditions: Vitreous Hemorrhage, Diabetic Retinopathy
Interventions: Vitrase; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2003
U.S. locations: 61
States / cities: Tucson, Arizona • Beverly Hills, California • Chula Vista, California + 51 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin glargine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 1,024 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Interventions: Specimen sample; Diagnostic Test
Lead sponsor: Sanguine Biosciences; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 20,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Diabetic Retinopathy
Interventions: ruboxistaurin, placebo; Drug
Lead sponsor: Chromaderm, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 731 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 36
States / cities: Artesia, California • Palm Springs, California • Poway, California + 33 more

Conditions: Choroiditis, Iridocyclitis, Iritis, Retinal Disease
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 4 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Macular Edema Secondary to Central Retinal Vein Occlusion
Interventions: VEGF Trap-Eye 2.0mg, Sham; Biological · Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 46
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 41 more

Conditions: Diabetic Macular Edema
Interventions: Brolucizumab, Aflibercept; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 566 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 39
States / cities: Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 33 more

Conditions: Retinal Vein Occlusion
Interventions: Minocycline, Placebo, Bevacizumab; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Posterior Vitreous Detachment, Diabetic Retinopathy
Interventions: annular array ultrasound exam; Procedure
Lead sponsor: Columbia University; Other
Eligibility: 60 Years to 90 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Kidney Failure, Chronic, Eye Diseases, Diabetic Retinopathy
Interventions: RetinaVue 100 camera; Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Behcet's Syndrome, Retinal Disease, Uveitis
Interventions: Daclizumab; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Von Hippel-Lindau Syndrome
Interventions: Ranibizumab, E10030; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Age-Related Macular Degeneration
Interventions: Sirolimus, Standard of Care intravitreal injections of anti-VEGF; Drug
Lead sponsor: Maturi, Raj K., M.D., P.C.; Individual
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Retinopathy, Retinal Vein Occlusion, Diabetic Retinopathy, Macular Degeneration
Interventions: Fluorescein sodium and Zeiss FF450 fundus camera, MB-102 and Zeiss FF450 fundus camera, Fluorescein sodium and commercially available optical angiography imaging system, MB-102 and commercially available optical angiography imaging system; Combination Product
Lead sponsor: MediBeacon; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Active Noninfectious Uveitis Affecting the Posterior Segment
Interventions: REGN7041; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Sacramento, California • Oak Park, Illinois • Nashville, Tennessee + 2 more

Conditions: Proliferative Diabetic Retinopathy, Diabetic Macular Edema
Interventions: Ranibizumab, Triamcinolone Acetonide, Sham injection, Focal/grid laser; Drug · Behavioral · Procedure
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 56
States / cities: Artesia, California • Beverly Hills, California • Irvine, California + 46 more

Conditions: Diabetes, Diabetic Retinopathy
Interventions: DVS supplementation; Dietary Supplement
Lead sponsor: ZeaVision, LLC; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Pomona, California • Tahlequah, Oklahoma

Conditions: Central Retinal Vein Occlusion
Interventions: aflibercept, bevacizumab; Drug
Lead sponsor: The Emmes Company, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 72
States / cities: Phoenix, Arizona • Tucson, Arizona • Mountain View, California + 60 more

Conditions: Diabetic Retinopathy
Interventions: BI 1467335, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 16
States / cities: Dothan, Alabama • Phoenix, Arizona • Beverly Hills, California + 13 more

Conditions: Diabetic Retinopathy
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 2
States / cities: Omaha, Nebraska

Conditions: Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy, Diabetic Retinopathy, Center-involved Diabetic Macular Edema, Center-involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
Interventions: INV-102; Drug
Lead sponsor: Invirsa, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

Study of Topical Ocular PAN-90806 in PDR

Assessment of EyeArt Performance With Retinal Cameras

A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)

Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage

Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

Reduction in the Occurrence of Center-Involved Diabetic Macular Edema

Evaluation and Treatment of Patients With Inflammatory Eye Diseases

Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

Minocycline to Treat Central Retinal Vein Occlusion

Annular Array Ultrasound in Ophthalmology

Feasibility Study of Retinal Screening Using the RetinaVue 100 Camera in Outpatient Dialysis Centers

HAT in Eye Complications of Behcet's Disease

A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab

Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMD

Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium

A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants

Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy

Diabetic Retinopathy Functional Evaluation Study: Monitoring Carotenoid Vitamins Treatment Using ERG

Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)

A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated.

Effect of Panretinal Photocoagulation on Optic Nerve Head Topography

Study of INV-102 Ophthalmic Solution in Adults With Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy